STOCK TITAN

24/7 Market News - Kraig Biocraft Advances Toward First-Ever Spider Silk Deliveries to Luxury and Performance Giants

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk development, announced significant progress toward commercialization in a shareholder letter. The company is in active discussions with three major global brands ready to receive initial spider silk shipments, including a luxury fashion brand, a high-end sportswear company, and a top-5 athletic equipment producer. KBLB's new double hybrid strain, set for 2025 launch, is expected to boost production by 25%+ monthly. The company's BAM-1 hybrid system has achieved industry-leading resilience, matching Chinese commercial silk hybrid standards. Several hundred kilograms of spider silk cocoons are awaiting processing, marking a transition to commercial-scale operations. The company reports a "revolution" in spider silk production technology over the past 14 months, with deliveries expected to begin in the second half of 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader nello sviluppo della seta di ragno, ha annunciato notevoli progressi verso la commercializzazione in una lettera agli azionisti. L'azienda è in trattative attive con tre grandi marchi globali pronti a ricevere le prime spedizioni di seta di ragno, tra cui un marchio di moda di lusso, un'azienda di abbigliamento sportivo di fascia alta e un produttore tra i primi cinque di attrezzature sportive. La nuova varietà ibrida doppia di KBLB, prevista per il lancio nel 2025, dovrebbe aumentare la produzione mensile di oltre il 25%. Il sistema ibrido BAM-1 dell'azienda ha raggiunto una resistenza leader nel settore, pari agli standard dei ibridi di seta commerciale cinesi. Diverse centinaia di chilogrammi di bozzoli di seta di ragno sono in attesa di lavorazione, segnando il passaggio a operazioni su scala commerciale. L'azienda riferisce di una "rivoluzione" nella tecnologia di produzione della seta di ragno negli ultimi 14 mesi, con le consegne previste per la seconda metà del 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB), líder en el desarrollo de seda de araña, anunció avances significativos hacia la comercialización en una carta a los accionistas. La empresa está en conversaciones activas con tres grandes marcas globales listas para recibir los primeros envíos de seda de araña, incluyendo una marca de moda de lujo, una compañía de ropa deportiva de alta gama y un productor de equipos deportivos entre los cinco principales. La nueva cepa híbrida doble de KBLB, prevista para su lanzamiento en 2025, se espera que aumente la producción mensual en más del 25%. El sistema híbrido BAM-1 de la compañía ha alcanzado una resistencia líder en la industria, igualando los estándares de los híbridos de seda comercial chinos. Cientos de kilogramos de capullos de seda de araña están esperando procesamiento, marcando la transición a operaciones a escala comercial. La empresa informa de una "revolución" en la tecnología de producción de seda de araña en los últimos 14 meses, con entregas previstas para la segunda mitad de 2025.
Kraig Biocraft Laboratories(OTCQB: KBLB)는 거미줄 개발 분야의 선두주자로서 주주 서한을 통해 상업화에 있어 중요한 진전을 발표했습니다. 회사는 초기 거미줄 출하를 받을 준비가 된 세계적인 대형 브랜드 세 곳과 활발히 논의 중이며, 이들에는 고급 패션 브랜드, 고급 스포츠웨어 회사, 그리고 5대 운동 장비 제조업체가 포함됩니다. KBLB의 새로운 이중 하이브리드 품종은 2025년 출시 예정이며, 월 생산량을 25% 이상 증가시킬 것으로 기대됩니다. 회사의 BAM-1 하이브리드 시스템은 중국 상업용 실크 하이브리드 표준과 동등한 업계 최고 수준의 내구성을 달성했습니다. 수백 킬로그램의 거미줄 고치가 가공을 기다리고 있어 상업 규모 운영으로 전환을 알립니다. 회사는 지난 14개월 동안 거미줄 생산 기술에 "혁명"이 일어났으며, 2025년 하반기에 납품이 시작될 것으로 보고 있습니다.
Kraig Biocraft Laboratories (OTCQB : KBLB), leader dans le développement de la soie d'araignée, a annoncé des progrès significatifs vers la commercialisation dans une lettre aux actionnaires. L'entreprise est en discussions actives avec trois grandes marques mondiales prêtes à recevoir les premières expéditions de soie d'araignée, incluant une marque de mode de luxe, une entreprise de vêtements de sport haut de gamme et un des cinq principaux producteurs d'équipements sportifs. La nouvelle souche hybride double de KBLB, prévue pour un lancement en 2025, devrait augmenter la production mensuelle de plus de 25 %. Le système hybride BAM-1 de la société a atteint une résistance de pointe dans l'industrie, équivalente aux normes des hybrides de soie commerciale chinois. Plusieurs centaines de kilogrammes de cocons de soie d'araignée attendent d'être traités, marquant une transition vers des opérations à l'échelle commerciale. L'entreprise rapporte une "révolution" dans la technologie de production de la soie d'araignée au cours des 14 derniers mois, avec des livraisons prévues pour la seconde moitié de 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein führendes Unternehmen in der Entwicklung von Spinnenseide, hat in einem Aktionärsbrief bedeutende Fortschritte auf dem Weg zur Kommerzialisierung bekannt gegeben. Das Unternehmen befindet sich in aktiven Gesprächen mit drei großen globalen Marken, die bereit sind, erste Lieferungen von Spinnenseide zu erhalten, darunter eine Luxusmodemarke, ein hochwertiger Sportbekleidungshersteller und ein Top-5-Hersteller von Sportausrüstung. Die neue doppelte Hybrid-Stammlinie von KBLB, die für 2025 geplant ist, soll die Produktion monatlich um über 25 % steigern. Das BAM-1-Hybridsystem des Unternehmens hat eine branchenführende Widerstandsfähigkeit erreicht, die den Standards chinesischer kommerzieller Seidenhybride entspricht. Mehrere hundert Kilogramm Spinnenseidenkokons warten auf die Verarbeitung, was den Übergang zu kommerziellen Produktionsmaßstäben markiert. Das Unternehmen berichtet von einer "Revolution" in der Spinnenseidenproduktionstechnologie in den letzten 14 Monaten, mit Lieferungen, die in der zweiten Hälfte des Jahres 2025 beginnen sollen.
Positive
  • Three major global brands are prepared to receive initial spider silk shipments, including a luxury fashion brand that accepted a quote
  • New double hybrid system expected to increase production output by 25%+ monthly
  • BAM-1 hybrid system achieved industry-standard disease resistance and reliability
  • Several hundred kilograms of spider silk cocoons ready for processing, indicating successful scale-up
  • Significant technological breakthrough in spider silk production over past 14 months
Negative
  • Commercial revenue generation has not yet begun
  • Deliveries to customers not expected until second half of 2025
  • Processing of stockpiled cocoons still pending

Shareholder Letter Reveals Breakthroughs, Global Brand Engagement, and Commercial Readiness

Denver, Colorado--(Newsfile Corp. - June 3, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, features the key highlights from a compelling shareholder letter by Kim Thompson, the CEO of Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk. The letter detailed groundbreaking scientific advancements, robust production progress, and a commercial pivot toward high-profile global partnerships, including these key takeaways:

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10481/254318_kraiglogo.jpg

Kraig Biocraft Laboratories Logo

Global Brands Standing by for First Spider Silk Shipments

Kraig Labs entered active commercial discussions with three major global brands that are preparing to receive initial spider silk shipments.

"We are in regular communication with three major global brands that are standing by to receive their first shipments of materials," the letter stated.

These include:

  • "An internationally renowned high-end luxury fashion brand that has already accepted a quote from Kraig Labs."
  • "A world leader in high-end performance sportswear with an approved budget to buy silk from us."
  • "One of the world's top 5 performance athletic equipment producers, looking for spider silk to integrate into their top-performing products."

"Currently, we expect to begin deliveries to these customers in the second half of this year."

New Double Hybrid Strain on Track for 2025 Launch

A major scientific milestone was confirmed with the announcement that the Company's next-generation production model—the double hybrid system—remains fully on track for deployment in 2025, which is critical to launching its double hybrid system, marking a significant leap in scalability and efficiency.

"Our longstanding plans were to field a new strain of silkworm for our double hybrid production system in the Summer of 2025... We were, therefore, ecstatic to announce that we created another world's first development on schedule."

This breakthrough is expected to boost production output by 25% or more monthly.

"The double hybrid model is designed to significantly improve our silk production rate, we expect by as much as 25+% per month."

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10481/254318_kraig1.jpg

Kraig Lab BAM-1 Recombinant Spider Silk Cocoons

BAM-1 Hybrid Demonstrates Industry-Leading Resilience

Kraig Biocraft's current BAM-1 hybrid system has already delivered major gains in disease resistance and reliability, matching the robustness and disease tolerance of the Chinese commercial silk hybrid, the regional gold standard.

"The BAM-1 appears to be on par with the Chinese commercial silk hybrid, which is the gold standard in that region for the production of mundane silk."

This leap in robustness has mitigated previous challenges with silkworm diseases and environmental stress. This resilience ensures more reliable production cycles, even in difficult environmental conditions like the current rainy season affecting global silk producers.

"Since rolling out the BAM-1, we have dealt with these routine challenges and have weathered these events with similar or identical effects as mundane silk producers utilizing the Chinese hybrid."

Work-in-Progress Inventory to Reflect True Output

The Company confirmed that several hundred kilograms of recombinant spider silk cocoon are now awaiting to be processed into finished silk. Kraig will begin including this in its work-in-progress (WIP) inventory accounting, to better reflect the company's shift to larger-scale production.

"We will expand the scope of our work-in-progress (WIP) material inventory to include recombinant spider silk cocoon that has been completed but not reeled."

This shift comes as hundreds of kilograms of spider silk cocoons await processing, laying the groundwork for larger-scale deliveries.

"In the first quarter of this year, we stockpiled several hundred kilograms of cocoon that are now waiting to be processed into finished silk."

This inventory expansion marks a transition from nominal production to commercial-scale operations.

Spider Silk Technology at a Tipping Point

The past year has seen what the Company describes as a "revolution" in its spider silk production technology.

"In short, there has been a revolution in our spider silk production technology over the past 14 months due to the introduction of BAM-1 and other improvements in the field and laboratory."

Robust strain development, improved disease tolerance, and steady production have laid the groundwork for scalable, high-yield manufacturing.

"As we meet our marks toward the initiation of the double hybrid, we anticipate our gains to accelerate further."

Commercial Focus and Execution at the Forefront

The letter also emphasized that spider silk production remains Kraig's exclusive and that execution is rapidly accelerating.

"As I hope we've made clear from our public disclosures over the last 18 months, we are 100% focused on the production of spider silk."

"In the last 8-10 months, we've been able to move faster to deliver on that commitment."

Revolution in Spider Silk Production: Over the past 14 months, Kraig Labs has achieved a "revolution" in its spider silk technology, overcoming historical robustness issues and positioning the company for accelerated growth as it prepares for the double hybrid system rollout.

The combination of scientific breakthroughs, increased output, and major brand engagement positions Kraig Biocraft for commercial revenue generation.

Focused Execution and Commercial Outlook

CEO Kim Thompson concluded the letter with a reaffirmation of Kraig Labs' unwavering mission:

"We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we've been able to move faster to deliver on that commitment."

"I believe the future for Kraig Labs and spider silk has never been brighter, and we thank you for your continued support."

Kraig emphasized that 100% of its focus is on spider silk production, and that accelerated progress over the past 8-10 months has positioned the company for its most important year yet. With foundational technology in place, the path to scaled commercialization and revenue generation is clearer than ever.

With next-gen technology on schedule, scaled inventory building underway, and three industry giants preparing to receive initial shipments, Kraig Biocraft Laboratories is transitioning from a research-centric biotech into a commercially viable materials science innovator.

Please click here for the full letter.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.

For more information, please visit: www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC Disclaimer

Please go to https://247marketnews.com/kblb-disclosure/ for disclaimer information.

About 24/7 Market News

24/7 Market News is a leading platform for public company market news. As a pioneer in digital media, we are committed to the rapid dissemination of financial market news and information. We excel in creating innovative public relations campaigns to help our clients effectively reach their target audience. 24/7 Market News offers paid coverage for public companies. For more information or PR inquiries, please contact: sales@247marketnews.com

Please go to www.247marketnews.com for further information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254318

FAQ

When will Kraig Biocraft (KBLB) begin delivering spider silk to customers?

According to the shareholder letter, KBLB expects to begin deliveries to customers in the second half of 2025.

What is the expected production increase from KBLB's new double hybrid system?

The double hybrid system is expected to boost production output by 25% or more per month.

How many major brands are ready to receive KBLB's spider silk?

Three major global brands are prepared to receive shipments: a luxury fashion brand, a high-end performance sportswear company, and a top-5 athletic equipment producer.

What is the current production status of KBLB's spider silk?

The company has stockpiled several hundred kilograms of spider silk cocoons that are awaiting processing into finished silk.

How does KBLB's BAM-1 hybrid system perform compared to industry standards?

The BAM-1 hybrid system matches the robustness and disease tolerance of the Chinese commercial silk hybrid, which is considered the regional gold standard.
Kraig Biocraft Laboratories In

OTC:KBLB

KBLB Rankings

KBLB Latest News

KBLB Stock Data

83.16M
784.01M
25.34%
0.01%
Specialty Chemicals
Basic Materials
Link
United States
Ann Arbor